1. Home
  2. News
  3. AdAlta Ltd.
  4. Investor briefing-AD-214 top line single dose safety results
More AdAlta Ltd. news
AdAlta Ltd.ASX: 1AD

Investor briefing-AD-214 top line single dose safety results

Mar 9, 2021 at 9:49 PM EST · Issued by AdAlta Ltd.

Filed with ASX · Mar 9, 2021 at 9:49 PM EST · 35 pages · English

On 6ix: 6ix.com/news/investor-briefing-ad-214-top-line-single-dose-safety-results

AdAlta Ltd. on 6ix

In the deck

  • AdAlta — Corporate Update (March 2021)35 slidesMar 10, 2021

Earlier from AdAlta

  • Appendix 4D and Interim Financial ReportFeb 25, 2021
  • FDA Orphan Drug Designation for AD-214Feb 23, 2021
  • Phase I HV extension to explore encouraging resultsDec 13, 2020
  • AGM PresentationNov 25, 2020
  • AusBiotech presentation including Phase I status updateOct 26, 2020

Later from AdAlta

  • Mutiple Dose Part Of Ad-214 Phase I Trial CommencedApr 18, 2021
  • AdAlta granted Japanese patent for AD-214May 18, 2021
  • GE Healthcare collaboration advances to next stageMay 23, 2021
  • R&D Tax Incentive FacilityJun 24, 2021
  • AdAlta secures AD-214 resupplyJul 1, 2021
All AdAlta news releases↗

Follow AdAlta into a list and get an email when it puts out news.

Follow AdAlta
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer